SLDB earnings call for the period ending March 31, 2021.
Compare SLDB Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Solid Biosciences Inc.
News & Analysis: Solid Biosciences Inc.
Investors appear to be skeptical about the biotech's latest clinical update.
Blame it on Sarepta.
The company announced plans to slash its head count and go all in on a single gene therapy. Is that wise or stubborn?
Early data for its side-effect-ridden gene therapy SGT-001 doesn't look very promising.
Investors expect stock-moving news from all of these drugmakers before the end of 2019.
A clinical trial evaluating the company's lead drug candidate was placed on a clinical hold -- for the third time.
The clinical-stage biopharma announced changes to its lead pipeline program. Will it be enough?
The gene therapy developer appears to be struggling to find a safe and effective dose of its experimental Duchenne muscular dystrophy treatment.
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.